Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients

Abstract The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to Febr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ting Chen, Jiayi Song, Hongli Liu, Hongmei Zheng, Changzheng Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c662a268e68d4192b8de4a7a4fbb1d08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c662a268e68d4192b8de4a7a4fbb1d08
record_format	dspace
spelling	oai:doaj.org-article:c662a268e68d4192b8de4a7a4fbb1d082021-12-02T16:53:02ZPositive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients10.1038/s41598-021-90351-y2045-2322https://doaj.org/article/c662a268e68d4192b8de4a7a4fbb1d082021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90351-yhttps://doaj.org/toc/2045-2322Abstract The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.Ting ChenJiayi SongHongli LiuHongmei ZhengChangzheng ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ting Chen Jiayi Song Hongli Liu Hongmei Zheng Changzheng Chen Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
description	Abstract The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.
format	article
author	Ting Chen Jiayi Song Hongli Liu Hongmei Zheng Changzheng Chen
author_facet	Ting Chen Jiayi Song Hongli Liu Hongmei Zheng Changzheng Chen
author_sort	Ting Chen
title	Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
title_short	Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
title_full	Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
title_fullStr	Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
title_full_unstemmed	Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients
title_sort	positive epstein–barr virus detection in coronavirus disease 2019 (covid-19) patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c662a268e68d4192b8de4a7a4fbb1d08
work_keys_str_mv	AT tingchen positiveepsteinbarrvirusdetectionincoronavirusdisease2019covid19patients AT jiayisong positiveepsteinbarrvirusdetectionincoronavirusdisease2019covid19patients AT hongliliu positiveepsteinbarrvirusdetectionincoronavirusdisease2019covid19patients AT hongmeizheng positiveepsteinbarrvirusdetectionincoronavirusdisease2019covid19patients AT changzhengchen positiveepsteinbarrvirusdetectionincoronavirusdisease2019covid19patients
_version_	1718382884967940096

Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients

Ejemplares similares